SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Active Biotech to Present at the UBS 2008 Global Life Sciences Conference
[September 17, 2008]

Active Biotech to Present at the UBS 2008 Global Life Sciences Conference


(Marketwire Via Acquire Media NewsEdge) LUND, SWEDEN, September 17 / MARKET WIRE/ --

Lund, Sweden, 17 September 2008 - Active
Biotech (OMX Nordic: ACTI)
is scheduled to present at the UBS Global Life Sciences Conference on
Tuesday, September 23 at the Grand Hyatt Hotel in New York City, US.
During the presentation, an update regarding Active Biotech's
development programs will be provided.

The presentation will include the Phase III projects laquinimod, a
novel oral immunomodulatory drug for the treatment of Multiple
Sclerosis, which is licensed to Teva Pharmaceutical Industries Ltd
and ANYARA, Active Biotech's novel concept for tumor therapy in a
Phase III study for renal cell cancer. Also, retrospective Phase I
bone scan evaluation data from the prostate cancer project TASQ will
be presented. An update will also be given on the SLE project 57-57
and the new project around the mode of action of the quinoline
technology.

The audio and slide presentation will be webcasted live and can be
accessed via the Active Biotech web site.

To access the live and replay presentations please go to -
www.activebiotech.com.

The presentation will take place on September 23, at 1:00 pm US
Eastern Time / 19:00 Central European Time.

About Active Biotech

Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a
biotechnology company with R&D focus on autoimmune/inflammatory


diseases and cancer. Projects in pivotal phase are laquinimod, an
orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis, as well as ANYARA
for use in cancer targeted therapy, primarily renal cancer. Further
key projects in clinical development comprise the three orally
administered compounds TASQ for prostate cancer, 57-57 for SLE and
RhuDex? for RA. Please visit www.activebiotech.com for more
information.

Active Biotech is required under the Financial Instruments Trading
Act to make the information in this press release public. The
information was submitted for publication at 11:00 a.m. CET on
September 17, 2008.


Contacts:

Active Biotech AB
G?ran Forsberg, VP Communication & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Copyright ? Hugin AS 2008. All rights reserved.

Copyright ? 2008 Marketwire

[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy